LUMA Vision, maker of a 4D cardiac imaging and navigation platform using machine learning, announced that it has secured $22 million in Series A3 funding.
The round was led by existing investors ABV Uni Fund, imec.xpand and EQT Lifesciences, and included new investors Bayern Kapital, Atlantic Bridge Growth Fund and an undisclosed strategic investor.
WHAT HE DOES
LUMA, from Trinity College Dublin, has developed a heart-focused 4D imaging and navigation platform called VERAFEYE, which enables real-time soft tissue imaging to aid intracardiac and endovascular navigation.
LUMA Vision, which has offices in Dublin and Munich, plans to use the funds to obtain FDA clearance in the United States for VERAFEYE, lay the foundation for commercialization in the United States and further develop its platform.
“Physicians need accurate, real-time point-of-care data in order to effectively treat patients,” Fionn Lahart, CEO of LUMA Vision, said in a statement. “Our goal with VERAFEYE is to provide physicians with the data and imaging they need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored to specific cardiology therapies, we believe VERAFEYE can be the foundation of medical imaging for many years to come. »
MARKET OVERVIEW
Other companies offering 4D technology include GE Healthwhich offers its Voluson i platform, a compact 4D ultrasound system aimed at women’s healthcare, and Japan’s Canon Medical System, formerly Toshiba Medical Systems, which offers its AI-powered Alphenix 4D CT technology.
